Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

Histone deacetylases (HDAC) are therapeutic targets in multiple cancers. ACY241, an HDAC6 selective inhibitor, has shown anti-multiple myeloma (MM) activity in combination with immunomodulatory drugs and proteasome inhibitors. Here we show ACY241 significantly reduces the frequency of CD138(+) MM ce...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leukemia
Egile Nagusiak: Bae, Jooeun, Hideshima, Teru, Tai, Yu-Tzu, Song, Yan, Richardson, Paul, Raje, Noopur, Munshi, Nikhil C., Anderson, Kenneth C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6537609/
https://ncbi.nlm.nih.gov/pubmed/29487385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0062-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak